CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

pazopanib

Trade name: votrient

Small moleculeapproved

Approved

Oct 19, 2009

Pazopanib (VOTRIENT) is an orally bioavailable multi-targeted tyrosine kinase receptor inhibitor. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR) -1 and -3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In an vitro study, pazopanib exerted anti-tumor effect through mechanisms including the Raf-MAPK/ERK (MEK)-extracellular signal-regulated kinase (ERK) pathway. It has good oral exposure and inhibits angiogenesis and tumor growth in mice. Pazopanib (VOTRIENT) was developed by GlaxoSmithKline for the treatment of solid tumours and age-related macular degeneration. However, Novartis acquired all the rights to the drug from GlaxoSmithKline. Pazopanib (VOTRIENT) is indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma. — NCATS

Clinical trial activity

264 trials · 201 clinical orgs · 9 marketing orgs

Phase 1
94
Phase 2
175
Phase 3
23
Phase 4
6

Earliest trial started Dec 1, 2002 (NCT00060151)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Sep 1, 2002

    Glaxo Wellcome — IND Organization

  3. Sep 1, 2002

    Glaxo Wellcome — IND Organization

  4. Jan 1, 2005

    GlaxoSmithKline — Earliest Phase 2 Sponsor(trial)

  5. Jan 1, 2006

    GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)

  6. Oct 19, 2009

    GlaxoSmithKline — Earliest FDA Approval

  7. Oct 19, 2009

    Novartis — NDA Secondary Org

  8. Oct 19, 2009

    GlaxoSmithKline — NDA Organization

  9. Oct 19, 2009

    Novartis — Marketing Organization

2020s

  1. Oct 19, 2023

    Apotex — Marketing Organization

  2. Oct 19, 2023

    Sun Pharmaceuticals — Marketing Organization

  3. Oct 19, 2023

    Teva — Marketing Organization

  4. Apr 23, 2024

    SciTech Development, LLC — Marketing Organization

  5. Dec 4, 2024

    Eugia Pharma — Marketing Organization

  6. Sep 4, 2025

    Torrent Pharmaceuticals Limited — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedOct 19, 2009

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Mol. weight
437.53 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • gw780604
  • gw 780604
  • gw-780604
  • gw 78603
  • gw 78603
  • gw786034
  • gw786034
  • gw786034
  • gw 786034
  • gw786034b
  • gw786034b
  • gw786034b
  • gw786034b
  • gw786034b
  • gw786034b
  • gw 786034b
  • gw-786034b
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib
  • pazopanib hcl
  • pazopanib hcl
  • pazopanib hcl
  • pazopanib hydrochloride
  • pazopanib hydrochloride
  • pazopanib hydrochloride
  • pazopanib hydrochloride
  • pazopanibum
  • pazopanibum
  • votrient
  • votrient
  • votrient
  • votrient
  • votrient
  • votrient

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07087158Phase 2Aug 10, 2025Imbioray (Hangzhou) Biomedicine Co., Ltd.
NCT06895733Phase 1/Phase 2 (Phase 2)Nov 27, 2024Tianjin Medical University
NCT06739395Phase 2Nov 1, 2024Tianjin Medical University
NCT06726421Phase 3Sep 18, 2024Sun Yat-Sen University
NCT06263231Phase 3Jun 28, 2024Intensity Therapeutics, Johns Hopkins University, Premier Research Group
NCT05949424Phase 4May 31, 2024University of Groningen
NCT06239272Phase 1/Phase 2 (Phase 2)Mar 27, 2024St. Jude Children's Hospital
NCT05679921Phase 2Mar 1, 2024Yonsei University
NCT05432791Phase 2/Phase 3 (Phase 3)Mar 30, 2023National Cancer Institute (NCI)
NCT05633381Phase 2/Phase 3 (Phase 3)Dec 9, 2022National Cancer Institute (NCI)
NCT05816642N/AAug 1, 2022Air Force Military Medical University, China, Anhui Medical University, Central South University, Changzhi Medical College, Chinese Academy of Medical Sciences, Fudan University, Fujian Medical University, Huazhong University of Science and Technology, Jiao Tong University, Nanjing Medical University, Nanjing University, Nantong University, Peking University, People's Liberation Army of China, Shaanxi Provincial People's Hospital, Shanxi Medical University, Sichuan University, Sun Yat-Sen University, University of Science and Technology of China, Wenzhou Medical University, Zhejiang University, Zhengzhou University
NCT05180695Phase 1/Phase 2 (Phase 2)Apr 15, 2022Centre Leon Berard, National Cancer Institute, France, Novartis
NCT05210413Phase 1/Phase 2 (Phase 2)Apr 1, 2022Fondation ARC, National Cancer Institute, France, Novartis, University of Bordeaux
NCT04741438Phase 3Mar 30, 2021Centre Leon Berard
NCT04199026Early Phase 1 (Phase 1)Jan 31, 2020National Cancer Institute (NCI), University of Texas at Houston
NCT03850964Phase 2/Phase 3 (Phase 3)Sep 30, 2019Augusta University, Cure HHT
NCT03850730Phase 1/Phase 2 (Phase 2)Sep 30, 2019Cure HHT, University of North Carolina at Chapel Hill
NCT03798106Phase 2Feb 11, 2019Yonsei University
NCT03735758Phase 4Nov 2, 2018GWT-TUD GmbH, University of Rostock
NCT03628131Phase 1/Phase 2 (Phase 2)Oct 31, 2018Government of Korea, Sungkyunkwan University
Showing 20 of 264 trials
Page 1 / 14

Organizations

Research & Development (201)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit984842004
National Cancer Institute (NCI)Government452842002
NovartisFor profit281042006
University of Texas at HoustonAcademic/Hospital111022007
Sungkyunkwan UniversityAcademic/Hospital9822010
Centre Leon BerardAcademic/Hospital7632010
National Comprehensive Cancer NetworkAcademic/Hospital7022011
Mayo ClinicAcademic/Hospital6122008
Harvard UniversityAcademic/Hospital5422010
University of MilanAcademic/Hospital5422009
Washington University in St. LouisAcademic/Hospital5422010
City of Hope National Medical CenterAcademic/Hospital4112010
Concerto HealthAIFor profit4422009
Northwestern UniversityAcademic/Hospital4322010
University of California, San FranciscoAcademic/Hospital4332012
University of HeidelbergAcademic/Hospital4422010
Bristol-Myers SquibbFor profit3122012
Case Western Reserve UniversityAcademic/Hospital3332002
Cornell UniversityAcademic/Hospital3212011
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital3112012
201 organizations
Page 1 / 11

Marketing (10)

OrganizationOrg typeRelationshipDate
ApotexFor profitMKTGOct 19, 2023
Eugia PharmaFor profitMKTGDec 4, 2024
Glaxo WellcomeFor profitINDSep 1, 2002
GlaxoSmithKlineFor profitNDAOct 19, 2009
NovartisFor profitNDA2Oct 19, 2009
NovartisFor profitMKTGOct 19, 2009
SciTech Development, LLCFor profitMKTGApr 23, 2024
Sun PharmaceuticalsFor profitMKTGOct 19, 2023
TevaFor profitMKTGOct 19, 2023
Torrent Pharmaceuticals LimitedFor profitMKTGSep 4, 2025